Liposomal ciproflaxin: Completed Phase II enrollment

Aradigm completed enrollment of 40 patients in the double-blind, placebo-controlled, Australian and New Zealand Phase II ORBIT-2 trial evaluating inhaled ARD-3150. Patients will receive ARD-3150 once ...